Drug intelligence / Profile preview

influenza vaccine surface antigen, inactivated

Development stage
Approved
Lead developer
CSL Seqirus
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Influenza vaccine surface antigen, inactivated, is an **inactivated viral vaccine** used for the **prevention of influenza** disease caused by various influenza A and B virus subtypes contained in the vaccine[1][2][4]. It contains surface antigens—**hemagglutinin (HA) and neuraminidase (NA)**—purified from influenza viruses that have been inactivated, often with an adjuvant like MF59 (squalene oil-in-water emulsion) in some formulations. The vaccine stimulates the immune system to produce antibodies against HA and NA, which neutralize and prevent cell entry of the influenza virus, providing active immunization[3][1][4]. It does not contain live viruses and cannot cause influenza[2][3]. Developed according to World Health Organization recommendations, strain composition is updated yearly to match circulating strains[1][2][4]. The main use is **seasonal influenza prophylaxis** in children, adults, and older adults, with specific products indicated for certain age groups[1][2][4].

Brand names
FluadAgrifluFluad Quadrivalent
Other names
inactivated influenza vaccine surface antigeninactivated influenza virus vaccine surface antigeninactivated influenza vaccine
02

Targets

HA (Hemagglutinin)Neuraminidase

Beyond the preview

Go deeper on influenza vaccine surface antigen, inactivated.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza vaccine surface antigen, inactivated.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call